Next Article in Journal
DNA Methylation Malleability and Dysregulation in Cancer Progression: Understanding the Role of PARP1
Next Article in Special Issue
Immunometabolic Markers in a Small Patient Cohort Undergoing Immunotherapy
Previous Article in Journal
Roles of Cullin-RING Ubiquitin Ligases in Cardiovascular Diseases
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomolecules
Volume 12
Issue 3
10.3390/biom12030418
biomolecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Adenosine-Metabolizing Enzymes, Adenosine Kinase and Adenosine Deaminase, in Cancer

by
Galina Zhulai
1,*,
Eugenia Oleinik
1,
Mikhail Shibaev
2 and
Kirill Ignatev
3
1
Institute of Biology, Karelian Research Centre, Russian Academy of Sciences, 185910 Petrozavodsk, Russia
2
Endoscopic Department, Baranov Republican Hospital, 185019 Petrozavodsk, Russia
3
Surgical Department no. 2, Republican Oncological Dispensary, 185002 Petrozavodsk, Russia
*
Author to whom correspondence should be addressed.
Biomolecules 2022, 12(3), 418; https://0-doi-org.brum.beds.ac.uk/10.3390/biom12030418
Submission received: 11 February 2022 / Revised: 5 March 2022 / Accepted: 6 March 2022 / Published: 8 March 2022
(This article belongs to the Special Issue Immunotherapy and Cancer)
Browse Figures
Versions Notes

Abstract

:
The immunosuppressive effect of adenosine in the microenvironment of a tumor is well established. Presently, researchers are developing approaches in immune therapy that target inhibition of adenosine or its signaling such as CD39 or CD73 inhibiting antibodies or adenosine A2A receptor antagonists. However, numerous enzymatic pathways that control ATP-adenosine balance, as well as understudied intracellular adenosine regulation, can prevent successful immunotherapy. This review contains the latest data on two adenosine-lowering enzymes: adenosine kinase (ADK) and adenosine deaminase (ADA). ADK deletes adenosine by its phosphorylation into 5′-adenosine monophosphate. Recent studies have revealed an association between a long nuclear ADK isoform and an increase in global DNA methylation, which explains epigenetic receptor-independent role of adenosine. ADA regulates the level of adenosine by converting it to inosine. The changes in the activity of ADA are detected in patients with various cancer types. The article focuses on the biological significance of these enzymes and their roles in the development of cancer. Perspectives of future studies on these enzymes in therapy for cancer are discussed.

1. Introduction

Cancer therapy based on the modulation of immune processes, such as immune checkpoint blockade and adoptive cell therapy, has achieved significant results. However, this approach does not work for most patients [1]. Therefore, the study of complex mechanisms of interaction between the tumor and the immune system and the search for new targets for therapy remains relevant.
Currently, the role of metabolism of purine nucleotides in the development of the tumor is well established. In normal conditions, adenosine is present in the human body in minor amounts (around 1 µM) and participates in various physiological processes including sleep, angiogenesis, and immune regulation [2,3]. Hypoxia, ischemia, and inflammation increase the levels of extracellular adenosine (>100 µM) in the tumor microenvironment (TME). In terms of oncogenesis, the adenosine pathway is considered to be a barrier to successful immunotherapy, which makes it an important therapeutic target [4]. Adenosine binds with adenosine receptors associated with G-proteins on the cellular surface. Their activation leads to the induction (A2A and A2B receptors) or inhibition (receptors A1 and A3) of intracellular production of cyclic adenosine monophosphate (cAMP). Stimulation of these receptors modulates the functions of inflammatory and immune cells, leading to the formation of immune-suppressive conditions in the TME, angiogenesis, and metastasis [4].
Extracellular over-expression of adenosine in the tumor tissue is primarily observed in extracellular adenosine triphosphate (ATP) released by the lesional tissue and immune cells [3]. While intracellular ATP is an important source of energy, extracellular ATP functions as a “signal of danger” directing phagocytes to the sites of inflammation and informing the immune system about pathogen-associated molecular patterns and tissue destruction. It occurs due to the activation of the inflammasome and the production of interleukin-1β and anti-inflammatory cytokines. Conversion of ATP into adenosine occurs due to the system of adenosine-producing enzymes, ecto-nucleoside triphosphate diphosphohydrolase (NTPDase1, CD39), and ecto-5′-nucleotidase (5′NT, CD73) that change inflammatory medium conditions to anti-inflammatory ones (Figure 1).
It was established that CD39, which hydrolyzes ATP into adenosine diphosphate (ADP)/adenosine monophosphate (AMP), and CD73, which mediates the subsequent breakdown of AMP into adenosine, plays a key role in the development of tumors [5]. Their expression and activity are elevated in the tumor tissue and blood and are often associated with clinical signs of the disease and unfavorable prognosis in some cancers [6,7,8,9,10,11]. During the past years, along with the canonical pathway of adenosine production by the ATP/CD39/CD73 axis, an alternative pathway for the formation of adenosine from extracellular nicotinamide adenine dinucleotide (NAD+) is discussed in cancer progression [12,13,14].
The levels of adenosine are regulated by adenosine-converting enzymes adenosine kinase (ADK) [15] and adenosine deaminase (ADA) [16]. ADK adds the residue of phosphoric acid to adenosine and converts it into AMP. ADA separates an amino group from adenosine with the formation of inosine. ADA Michaelis constant (Km) for adenosine is 25–150 µM (depends on the isoform), while ADK Km is approximately 1 µM. Since ADK affinity to adenosine is higher, ADK is considered to be the enzyme responsible for the regulation of the level of adenosine in physiological conditions [17]. Besides, the level of adenosine is controlled by bidirectional nucleoside transporters [3,18].
Currently, the therapeutic potential of inhibition of ectonucleotidase enzymes CD39 and CD73, that breaks down ATP to adenosine, and adenosine receptor A2A is established in preclinical studies and is being tested in phase I/II of clinical studies on oncologic patients [4]. These targets (CD39, CD73, A2AR) are actively studied. However, in the development of the adenosine-regulating approach, numerous enzymatic pathways that control the balance of adenosine-ATP, are understudied. Besides, intracellular regulation of adenosine is underestimated. Thus, the study of other components of adenosine metabolism and search for their associations with immune disorders in the conditions of tumor development are relevant. This review contains the latest data on the effect of adenosine on cells in the TME. It focuses on enzymes involved in the metabolism of adenosine-ADK and ADA and provides an overview of biological significance of ADK and ADA and their role in the development of tumor. Perspectives of further studies on these enzymes for the therapy of oncologic diseases are discussed.

2. The Effect of Adenosine on Cells in the Tumor Microenvironment

Tumor hypoxia and inflammation alter the microenvironment to regulate tumor growth and suppress antitumor immune reaction [19]. Adenosine can regulate both innate and adaptive immune responses [3]. Various transcriptional factors, signaling pathways, and cytokines contribute to the accumulation of adenosine in the TME [19,20,21,22]. Adenosine affects tumor cells and tumor-infiltrating cells by the activation of adenosine receptors (Figure 2).
Receptors A1 (A1R) and A2A are highly affine to adenosine. In physiological conditions, adenosine functions via these receptors, while A2B and A3 are low affine receptors [3]. The type of G proteins activated in the stimulated cells determines the effect of each adenosine receptor. A1R and A3R are associated with Gi, Gq, and Go proteins. The A1R or A3R ligation on the immune cells can activate immune reactions due to the inhibition of adenylate cyclase activity and a decrease in the levels of cAMP. A2AR and A2BR are Gs-coupled. They induce the enzymatic activity of adenylyl cyclase and increase the intracellular level of cAMP. Besides, through cAMP activation, adenosine receptors are associated with MAPK, PKA, and EPAC signaling that control gene transcription, metabolism, proliferation, and apoptosis, which are important for tumor progression [3,4].
Adenosine binds with A2AR at CD4+ and CD8+ effector T cells and natural killer (NK) cells, which suppresses their functions [3]. This limits their anti-tumor activity and induces the expression of immune regulatory molecules cytotoxic T-lymphocyte associated protein 4 (CTLA-4) and programmed cell death 1 (PD-1) [23]. It should be mentioned that in patients with cancer, stimulation of A2AR delays the maturation of NK cells and inhibits their cytotoxic activity [24,25]. The expression of Fas-ligands, granzyme b, perforin, and TNF-related apoptosis-inducing ligand on CD8+ T-cells decreases after binding of adenosine with A2AR [26]. The results of experimental studies demonstrate that the blockade of A2AR on T cells suppresses tumor progression [27,28].
On the contrary, A2AR and A2BR ligation on anti-inflammatory cells, such myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Treg), induces their activation and expansion [29,30,31]. MDSCs and Treg cells can suppress the proliferation and functioning of effector cells and prevent the effective anti-tumor immune response. Besides, A2BR activation stimulates the polarization of macrophages into anti-inflammatory M2 type [32]. Such macrophages contribute to tumor progression and metastasis by producing immune-suppressing factors such as indoleamine 2,3-dioxygenase, arginase, and transforming growth factor β (TGF-β). Besides, A2BR and A1R activation on tumor-infiltrating neutrophils enhances the production of metalloproteases and contributes to metastasizing [32].
Some studies have highlighted the importance of the activation of adenosine receptors on tumor cells for their proliferation, survival, migration, and invasivity [33,34,35,36,37]. Besides, adenosine stimulates angiogenesis via A2BR and A2AR activation on endothelial cells [32] and angiotensin-mediated differentiation of dendritic cells (DC) [38,39]. For these reasons, adenosine receptors are actively studied. Currently, blockage of A2AR and/or A2BR, A3AR by monoclonal antibodies or small molecules is being studied in phase I-II of clinical studies on anti-tumor immunotherapy [4,37].

3. Adenosine Kinase

3.1. Biological Significance of ADK

ADK belongs to the family of ribokinases and is a key enzyme for the removal of extracellular adenosine by its phosphorylation into 5′-adenosine monophosphate (AMP) [15] (Figure 1). Regulating the availability of adenosine, ADK is an important link in complicated homeostatic and metabolic networks. The balance of adenosine and ADK is strictly maintained in healthy cells and the changes in the expression of ADK lead to the activation of adenosine receptors, which often determines the role of ADK in the development of pathologies [40].
Apart from its role in purine metabolism, ADK is involved in the regulation of transmethylation. During this biochemical reaction, the methyl group formed from the donor S-adenosylmethionine (SAM) is transferred onto an acceptor (lipids, dopamine, and DNA). The resulting product of all transmethylation reactions, S-adenosylhomocysteine (SAH), is further cleaved by SAH hydrolase (SAHH) into adenosine and homocysteine. In this reaction, adenosine is a by-product. If it is not completely deleted by ADK, it leads to the accumulation of SAH, which inhibits various transmethylation reactions necessary for a wide range of cellular processes [41]. The necessity of ADK enzyme for the organism was experimentally shown by Boison et al. [42]. ADK knockout mice had lethal phenotype. Homozygote ADK−/− mice normally developed during embryogenesis. However, four days after birth, they developed microvesicular hepatic steatosis and die 14 days later, demonstrating a reduction in ATP deposits, inhibition of transmethylation reactions, and accumulation of adenosine. In humans, inborn deficiency of ADK is detected in patients with hypermethioninemia, encephalopathy, and pathological liver functioning, demonstrating disorders in methionine and adenosine metabolism [43,44]. On the contrary, overexpression of ADK and adenosine deficiency can lead to nervous system pathology, in particular, to the development of epilepsy because adenosine acts as an inhibitory neuromodulator for neuronal cells and has an anticonvulsant effect [45].
Being a regulator of transmethylation, ADK can participate in the modulation of DNA methylation. This epigenetic mechanism plays an important role in the embryonal and fetal development of mammals, and aberrant methylation of DNA is typical for some pathologies. In particular, its significance was shown in the cases of cancer and neurologic disorders [46]. Presently, the role of ADK in the methylation of DNA is not determined. According to the studies performed on experimental models, there is an association between the alterations in the expression of ADK and changes in DNA methylation in patients with epilepsy, brain lesion, vascular inflammation, angiogenesis, atherosclerosis, and cancer, as well as the influence of pharmacological blockade of ADK on the level of global hypermethylation [41].
ADK enzyme exists in two isoforms that are similar in biochemical and kinetic properties [47] (Table 1). Structurally, isoforms are identical excluding n-terminus, wherein the long isoform (ADK-L) contains additional 20–21 amine acids that are replaced by four amino acids in a short isoform (ADK-S). These isoforms are formed as a result of alternative splicing [48]. Western blot analysis of rat tissue showed that the expression of a long isoform dominated in the heart and spleen, and a short isoform in the brain. A high level of expression of both isoforms was established for the kidneys, liver, lungs, and pancreas [48].
Besides, ADK isoforms are characterized by various intracellular localization. ADK-L is located in the nucleus and ADK-S–in the cell cytoplasm [49]. Various localization of isoforms suggests differences in functioning. ADK-S controls the extracellular level of adenosine and mediates the degree of activation of adenosine receptors and ADK-L regulates epigenetic functions. ADK-L participates in the reaction of SAM-dependent transmethylation, which induces DNA and histone methylation. This is contributed by the presence of ADK-L, methyltransferase, and SAH in the cellular nucleus [41]. A high level and activity of ADK-L are associated with high global methylation of DNA [50]. It was shown that BHK-AK2 cells that express ADK-L demonstrate an increase in the global methylation of DNA by 400%, while the cells with ADK-S expression—only by 50%. These data suggest that both isoforms can be involved in epigenetic regulation.
Changes in the expression of isoforms of ADK play an important role in the development of the brain. During early postnatal development of the rat brain, the expression of ADK undergoes a coordinated revolutionary shift from the primarily neuronal to the primarily astrocytic pattern of expression. The studies showed a fast decrease in the expression of neuronal transcripts of ADK-L and the growth of astroglial transcripts of ADK-S within the first two weeks of postnatal development of the rat brain [51]. Besides, the main role in the expression of ADK-L was shown with an influence of an external irritant. The expression of an ADK-L isoform contributed to the regulation of proliferation of neuronal stem cells after traumatic brain damage [52].
Recently, the involvement of ADK in the biosynthesis of an important metabolic cofactor NAD+ had been demonstrated [53]. Dihydronicotinamide ribose (NRH) is a precursor for the synthesis of NAD+. It reduces into NAD+ via a pathway, wherein ADK acts as an NRH kinase. Pharmacologic or genetic inhibition of ADK blocks the synthesis of reduced nicotinamide mononucleotide and suppresses NRH-mediated biosynthesis of NAD+ in vitro and in vivo.
ADK, as an important regulator of adenosine level, modulated various cellular processes, including sleep homeostasis [54]. It was shown that mice with transgene overexpression of ADK spent less time sleeping in comparison with wild-type mice [55]. Another study on astrocyte-selective ADK knockout mice demonstrated an elevated level of homeostatic sleep drive associated with adenosine [56]. ADK acts as a highly sensitive and important metabolic sensor of glial ratio ATP/ADP and AMP, directly controlling the levels of intracellular adenosine.
In addition to nervous system disorders [50,52,57], the changes in the level of ADK enzyme attract researchers who study diabetes [58,59], vascular inflammation [60,61], and cancer [5,62].

3.2. The Role of ADK in Cancer

The survival and expansion of tumor cells have a close association with adenosine metabolism [5]. All adenosine receptors (A1, A2a, A2b, and A3) can take part in carcinogenesis, exerting a pro-tumor or anti-tumor effect. An increased level of adenosine in TME exerts an immune suppressing effect, primarily mediated via an excessive activation of the Gs-bonded A2A receptor on the immune cells [63]. Hypoxia-inducible factor 1α (HIF-1α) contributes to the accumulation of adenosine. Hypoxia–A2A-adenosinergic signaling inhibits the T-cell receptor–triggered production of proinflammatory cytokines (such as IFNγ) and redirects the immune response to the expression of immunosuppressive factors, in particular, a TGF-b, interleukin (IL)-10, CTLA-4, and activation of Treg cells [64]. ADK, as a regulator of the level of adenosine, can facilitate in carcinogenesis and affect immune processes (Table 2).
It was shown that in patients with cancer, the levels of adenosine in tumor cells are regulated primarily by ADK-mediated phosphorylation to AMP and not the effect of ADA. This process is hypoxia-independent [13]. However, currently, there is no clear understanding of the role of ADK in the development of tumors. Thus, it was shown that the tumor tissue of patients with colorectal cancer had an elevated level of ADK gene expression and ADK activity in comparison with healthy tissue [65,66]. Patients with glioma also showed enhanced expression of the gene and protein of ADK in both the nucleus and cytoplasm of tumor cells [67]. On the contrary, patients with liver cancer had decreased levels of ADK in tumor tissue in comparison with healthy tissue [68]. The expression of ADK isoforms was different. Besides, decreased expression of ADK was associated with liver cancer relapse. The study on a model of transgene mice with deficient expression of ADK in the liver revealed their enhanced sensitivity to acute toxic effects of a carcinogen (diethylnitrosamine) and associated lethality.
The differences in the expression of two ADK isoforms are observed in the cases of breast cancer [62]. The changes in the tumor tissue primarily concerned ADK-L in comparison with healthy tissue. Its expression was enhanced. Suppression of expression of ADK-L and ADK-S led to a decrease in cell proliferation, deletion, and migration of cultivated tumor cells of breast cancer. Knockdown of ADK-L gene decreases gene expression of matrix metalloproteases, cyclin D2, and molecules of adhesion, which suggests the potential role of ADK-L in the mitogenesis, cancerogenesis, and invasion. Besides, a recent study on the epigenetic role of ADK-L on tumor cell lines revealed a direct association between the expression of ADK and DNA methylation. The application of specific ADK inhibitors decreased the level of global DNA methylation in HeLa cells in a dose-dependent manner [69].
Another mechanism of ADK-mediated effect on tumors can be epigenetic regulation of pro-angiogenic factors. The formation of new blood vessels often occurs in response to hypoxia in the cases of cancer or ischemic disorders. Earlier, the study showed that hypoxia was associated with a suppression of ADK functioning and limitation of phosphorylation of intracellular adenosine to AMP [70]. Besides, deficiency of ADK in the endothelial cells increases the level of intracellular adenosine and stimulates DNA hypomethylation in the promoter regions of some pro-angiogenic genes, in particular, the gene of vascular-endothelial growth factor receptor 2 (VEGFR2). It leads to the proliferation and migration of cells in vitro, improves wound healing, and stimulates angiogenesis induced by ischemia in experimental animals in vivo [71]. Thus, the association between ADK and cell proliferation in the process of development, correlation of changes in the expression of this enzyme in the tumor tissue, as well as association of epigenetic changes that are observed during cancer, make ADK, in particular, ADK-L, a promising therapeutic target.

4. Adenosine Deaminase

4.1. The biological Significance of Adenosine Deaminase

ADA enzyme is an important protein in the purine metabolism and acts as a catalyzer and co-stimulator, as well as provides an intercellular connection [16]. ADA deaminates adenosine and 2′-deoxyadenosine to inosine and 2′-deoxyinosine, respectively. In humans, ADA has two isoforms, ADA1 and ADA2 (Table 1). ADA1 is found in all human tissues. It is highly expressed by T and B cells [72,73] and provides around 90% of all ADA activity. The main function of ADA1 is in the regulation of the intracellular level of adenosine. Mutations with the loss of function in the gene ADA1 can lead to hereditary immune deficiencies, known as severe combined immunodeficiency (SCID) in 15% of cases. SCID is associated with a dysfunction of circulating T, B, and NK cells and severe lymphopenia because of intracellular accumulation of toxic products of adenosine and cell apoptosis [73].
ADA1 can have an extracellular effect that binds to the surface of cells with dipeptidyl peptidase 4 (CD26) and adenosine receptors A1, A2A, and A2B on the surface of immune cells. This determines its enzyme-independent adaptive function. Due to a double bond with both CD26 on T-cells and with A2AR on DC, ADA1 can contribute to the formation of immunological sinapsis [74,75]. Moreover, its interaction with CD26 regulates lymphocyte-epithelial cell adhesion [76]. It is suggested that enzymatic activity of ADA1 is necessary for immune cells for the protection from suppression mediated by Treg cells that are involved in the generation of extracellular adenosine [77,78]. In lack of ADA1, adenosine can limit the proliferation of T cells and the secretion of cytokines by the activation of the A2AR. Besides, ADA1 can interact as an allosteric effector that controls the program of follicular T-helpers enhancing the affinity of adenosine to A1R (primarily expressed by T cells and B cells) and functionality of the receptor. This leads to controlled signaling to CD26/IL-2/IL-6 in addition to a decrease in the levels of adenosine and, thus, availability of metabolites for other adenosine receptors [79].
On the contrary, isoform ADA2 is not widely found in human organisms. Its structure, cellular localization, and expression are different from ADA1 [80]. It has a more open and hydrophilic catalytic center, which is reflected in enzymatic capacity. In particular, the ADA2 Km value is 100-fold higher for deamination of adenosine than ADA1. Besides, ADA2 is not more active than ADA1 at pH 6.9. Thus, in physiological conditions, its deamination function is limited. ADA2 works well in weak acidic acid, for example, in hypoxic conditions [80].
If ADA1 has intracellular localization, ADA2 forms homodimers and secrets into extracellular space. ADA2 is highly expressed in myeloid cells and produced by activated monocytes, macrophages, and DC in the sites of inflammation and TME [81]. Besides, ADA2 is secreted by monocytes during differentiation into macrophages or DC, and its secretion is regulated by interferon (IFN)-γ. Immune-inflammatory diseases such as systemic lupus erythematosis, rheumatoid arthritis, Chrone’s diseases, tuberculosis, and HIV infection, are associated with an enhancement in the activity of ADA2, which can be used as a biomarker of the disease and response to treatment, especially in patients with tuberculosis [82,83,84,85]. It is reported that ADA2 can act as a growth factor [86]. ADA2 exerts autocrine activity, induces the proliferation of monocytes, and contributes to the differentiation of anti-inflammatory macrophages M2 [87]. There is also indirect evidence of the possible role of ADA2 as an endothelial growth factor [88].
Mutations in the ADA2 gene lead to an inflammatory disease called ADA2 deficiency (DADA2), which is characterized by inflammatory vasculopathy and early strokes that are frequently associated with hypogammaglobulinemia [73,89]. DADA2 is less expressed than SCID-ADA. DADA2 treatment includes hematopoietic stem cell transplantation. Without treatment, ADA1-deficient SCID is fatal at an early age. Its treatment primarily includes hematopoietic stem cell transplantation as well as enzyme replacement therapy and gene therapy [90]. Although the lack of functional ADA1 and ADA2 leads to a disturbance in the immune function regulation, the lack of one functional element is not compensated by the presence of the other. It suggests that ADA1 and ADA2 play different roles [73]. Kaljas et al. showed that this can be explained by binding with various immune cells [72]. ADA1 binds with T cells and NKT cells that express CD26 receptors, and ADA2 binds with neutrophils, monocytes, B cells, NK cells, and CD39+ Treg cells, that do not express CD26. Adenosine deaminases, which bind with the surface of these cells, can regulate their activity via a decrease in the concentration of extracellular adenosine. Besides, they can participate in the formation of immunological synapsis, regardless of their enzymatic activity.
Moreover, ADA plays a role in male fertility [91,92]. Another study that included newborn children showed that ADA1 and ADA2 demonstrated persistent changes within the first weeks and months of life and correlated with the levels of cytokines and chemokines in the plasma. Thus, ADA may play a functional role in the immune ontogenesis of a human [93,94]. ADA can be examined as a target in anti-tumor therapy due to immune-modulating properties and the ability to limit the concentration of adenosine.

4.2. The Role of ADA in Cancer

An intensification of ADA activity is observed in patients with different diseases, including cancer (Table 3). There is an association between a high activity of ADA and the stage of disease for gastric, bladder, breast, colorectal, and renal cell cancer [66,95,96,97,98,99,100,101,102]. It is reported that for some cancers, a decrease in the activity of ADA is associated with a progression of such diseases as head and neck, prostate, and laryngeal squamous cancer [103,104,105]. In the case of lung cancer, the significance of ADA activity is controversial. A decreased activity of ADA in the peripheral lymphocytes is observed in patients with stage IV cancer [106]. However, the level of ADA has a diagnostic significance in the bronchoalveolar lavage fluid and can be used as an additional parameter for the evaluation of malignancy when a biopsy can be complicated [107]. Noteworthy, the activity of ADA (ADA1 and ADA2) changes during the interaction of tumor cells (triple-negative breast cancer) with lymphocytes, macrophages, and endothelial cells in vitro, providing unfavorable phenotype and contributing to cancer progression. An association between the activity of ADA2 in the plasma of patients with breast cancer with a pro-tumor M2 phenotype of macrophages, as well as the activity of ADA1, and endothelial cell dysfunction or inflammatory parameters [102] was shown.
In patients with head and neck cancer, the possibility to limit the ADA activity and CD26 expression in effector T cells and CD3+ exosomes derived from T cells [105] has been seen. In the early stages of the disease, exosomes and T cells function relatively normally, but along with the progression of the disease, the expression of ADA/CD26 gets suppressed.

5. Targeting ADK and ADA in the Cancer Therapy

The accumulation of extracellular adenosine prevents effective anti-tumor immunotherapy [5]. Thus, enzymes that regulate the levels of adenosine can be useful tools for the development of new approaches that would improve the treatment effectiveness.
Enhancement of ADA1 expression can not only decrease the levels of adenosine in TME but also accumulate inosine. It was shown that T cells can use adenosine as an alternative source of carbon to synthesize glucose for the maintenance of their functions in glucose-deficient conditions in vitro [108]. The addition of inosine enhanced the anti-tumor effect of immune checkpoints (PD-L1/PD-1) and the adaptive transfer of T cells into tumors in the experimental models.
Recently, PEGylated ADA2 (PEGADA2) was studied on preclinical cancer models, providing promising results for clinical application [109]. In mice, PEGADA2 inhibited tumor growth depending on the level of the enzyme activity and affected the immune response. Another study showed that chimeric antigen receptor (CAR)-engineered T cells, which overexpress ADA, increased the resistance to exhaustion of CAR-T cells. At the same time, tumor burden decreased, which shifted TME to the direction of anti-inflammatory immunity in experimental models [110].
The application of ADA inhibitors for the treatment of malignant pathology has been reported. This approach can lead to the accumulation of adenosine in the sites of inflammation. Besides, it can reduce the production of free radicals, which are a known side-effect of numerous anti-tumor drugs. ADA can deaminate and inactivate adenosine analogs that are used in chemotherapy [16]. Thus, ADA inhibitors (pentostatin and cladribine) are applied in the treatment of a rare hematological malignant pathology—hairy cell leukemia [111]. Unlike pentostatin, another ADA inhibitor erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA) can induce the apoptosis of malignant pleural mesothelioma (MPM), which is an aggressive tumor that does not have effective therapy. It was shown under experimental conditions that EHNA prevents the proliferation of MPM cells due to an increase in the level of extracellular adenosine in vitro and reduces tumor growth in mice inoculated with MPM cells in vivo [112]. The inhibition of ADA by 2′deoxycoformycin (dCF) has been reported to reduce tumor size and its growth in mice with modeled breast cancer in vivo and in human tumor cells in vitro [113]. dCF suppresses the migration and invasion of tumor cells via the activation of A2AR and A3R as well as the adhesion and transmigration of tumor cells through the layer of endothelial cells by the stimulation of A2AR.
Primarily, ADK is a therapeutic target for conditions such as epilepsy, pain syndrome, and inflammation. The protective effect of ADK inhibitors has been shown [114]. Lately, new data have appeared on the role of ADK-L in the regulation of cellular proliferation in the pancreas [58,115] and nervous system [52] as well the involvement of ADK-L in mitogenesis, carcinogenesis, and tumor invasion [62]. Besides, the epigenetic role of ADK-L has been shown and is actively studied. It is known that hypermethylation of DNA is a pathological feature of various cancers [116,117]. The inhibition of ADK-L can contribute to the reverse of DNA hypermethylation phenotype in cancer [69]. Modulation of ADK-S is also possible to overcome the immune-suppressive barrier in the TME because ADK-S can regulate the level of adenosine and activation of adenosine receptors [118]. Considering the changes that occur in the expression of ADK in the tumor tissue, it can be suggested that ADK is a potential diagnostic marker and a perspective target for anti-tumor therapy.

6. Conclusions

The regulation of the level of adenosine has therapeutic potential for cancer therapy (Figure 3). Currently, the studies experimentally and clinically confirmed the effectiveness of CD39-, CD73-blocking antibodies, and antagonists of adenosine A2A receptor as agents that decrease the levels of adenosine and block their signaling [5]. Inhibition of the adenosinergic pathway improves the effectiveness of blockade of other immune checkpoints, like PD-1/PDL-1 [119] or CTLA-4 [120] as well as the effectiveness of CAR-T cell therapy [121] and adaptive T cell therapy [122]. In experimental studies, combined therapy against CD73 and CD39 or CD73 and A2AR showed better response in comparison to monotherapy with CD73, CD39, or A2AR [123,124,125]. This indicates that one-target therapeutic agents do not prevent the complete generation of adenosine or signaling. It is generally accepted that tumor cells can form an immune-suppressing microenvironment with increased concentration of extracellular adenosine [4]. However, the intracellular metabolism of adenosine in patients with cancer is understudied. It is difficult to completely inhibit the synthesis of adenosine because of the variety of enzymes and metabolic pathways that contribute to its production. Targeting enzymes in the TME that decrease the levels of adenosine (such as ADA and ADK) can significantly prevent the activation of adenosine receptors and enhance cancer immunotherapy.
Considering its epigenetic role, ADK can become a promising target for the therapy of tumors with hypermethylated phenotypes. Since there are differences in the functioning of ADK-L and ADK-S, further studies are required on the role of each isoform in the maintenance of ATP/adenosine in cases with cancer. Currently, the main obstacle to such studies is a lack of isoform-specific inhibitors, in particular, highly selective for a nuclear isoform of ADK-L [41]. Besides, the contribution of ADK-S into DNA methylation is understudied [50].
Thus, the application of ADK and ADA can become a perspective approach to anti-tumor therapy. Currently, they are actively being studied for various malignant pathologies. It is necessary to have a clear and detailed understanding of the mechanism of action of these enzymes in tumor to introduce them in clinical practice.

Author Contributions

Writing—original draft preparation, G.Z., M.S. and K.I., writing—review and editing, G.Z. and E.O., supervision, G.Z. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Russian Science Foundation (RSF), grant number 27-75-00013, https://rscf.ru/en/project/21-75-00013/, accessed on 10 February 2022.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Esfahani, K.; Roudaia, L.; Buhlaiga, N.; Del Rincon, S.V.; Papneja, N.; Miller, W.H. A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future. Curr. Oncol. 2020, 27, 87–97. [Google Scholar] [CrossRef] [PubMed]
  2. Baghbani, E.; Noorolyai, S.; Shanehbandi, D.; Mokhtarzadeh, A.; Aghebati-Maleki, L.; Shahgoli, V.K.; Brunetti, O.; Rahmani, S.; Shadbad, M.A.; Baghbanzadeh, A.; et al. Regulation of Immune Responses through CD39 and CD73 in Cancer: Novel Checkpoints. Life Sci. 2021, 282, 119826. [Google Scholar] [CrossRef] [PubMed]
  3. Antonioli, L.; Fornai, M.; Blandizzi, C.; Pacher, P.; Haskó, G. Adenosine Signaling and the Immune System: When a Lot Could Be Too Much. Immunol. Lett. 2019, 205, 9–15. [Google Scholar] [CrossRef] [PubMed]
  4. Churov, A.; Zhulai, G. Targeting Adenosine and Regulatory T Cells in Cancer Immunotherapy. Hum. Immunol. 2021, 82, 270–278. [Google Scholar] [CrossRef]
  5. Boison, D.; Yegutkin, G.G. Adenosine Metabolism: Emerging Concepts for Cancer Therapy. Cancer Cell 2019, 36, 582–596. [Google Scholar] [CrossRef]
  6. Shevchenko, I.; Mathes, A.; Groth, C.; Karakhanova, S.; Müller, V.; Utikal, J.; Werner, J.; Bazhin, A.V.; Umansky, V. Enhanced Expression of CD39 and CD73 on T Cells in the Regulation of Anti-Tumor Immune Responses. OncoImmunology 2020, 9, 1744946. [Google Scholar] [CrossRef] [Green Version]
  7. Zhulai, G.A.; Churov, A.V.; Oleinik, E.K.; Romanov, A.A.; Semakova, V.M.; Oleinik, V.M. Activation of CD4+CD39+ T Cells in Colorectal Canser. Bull. Russ. State Med. Univ. 2018, 3, 47–53. [Google Scholar] [CrossRef]
  8. Cai, X.-Y.; Ni, X.-C.; Yi, Y.; He, H.-W.; Wang, J.-X.; Fu, Y.-P.; Sun, J.; Zhou, J.; Cheng, Y.-F.; Jin, J.-J.; et al. Overexpression of CD39 in Hepatocellular Carcinoma Is an Independent Indicator of Poor Outcome after Radical Resection. Medicine 2016, 95, e4989. [Google Scholar] [CrossRef]
  9. Koivisto, M.K.; Tervahartiala, M.; Kenessey, I.; Jalkanen, S.; Boström, P.J.; Salmi, M. Cell-Type-Specific CD73 Expression Is an Independent Prognostic Factor in Bladder Cancer. Carcinogenesis 2019, 40, 84–92. [Google Scholar] [CrossRef]
  10. Wang, J.; Matosevic, S. NT5E/CD73 as Correlative Factor of Patient Survival and Natural Killer Cell Infiltration in Glioblastoma. J. Clin. Med. 2019, 8, 1526. [Google Scholar] [CrossRef] [Green Version]
  11. Loi, S.; Pommey, S.; Haibe-Kains, B.; Beavis, P.A.; Darcy, P.K.; Smyth, M.J.; Stagg, J. CD73 Promotes Anthracycline Resistance and Poor Prognosis in Triple Negative Breast Cancer. Proc. Natl. Acad. Sci. USA 2013, 110, 11091–11096. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Horenstein, A.L.; Chillemi, A.; Zaccarello, G.; Bruzzone, S.; Quarona, V.; Zito, A.; Serra, S.; Malavasi, F. A CD38/CD203a/CD73 Ectoenzymatic Pathway Independent of CD39 Drives a Novel Adenosinergic Loop in Human T Lymphocytes. OncoImmunology 2013, 2, e26246. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Losenkova, K.; Zuccarini, M.; Karikoski, M.; Laurila, J.; Boison, D.; Jalkanen, S.; Yegutkin, G.G. Compartmentalization of Adenosine Metabolism in Cancer Cells and Its Modulation during Acute Hypoxia. J. Cell Sci. 2020, 133, jcs241463. [Google Scholar] [CrossRef]
  14. Morandi, F.; Morandi, B.; Horenstein, A.L.; Chillemi, A.; Quarona, V.; Zaccarello, G.; Carrega, P.; Ferlazzo, G.; Mingari, M.C.; Moretta, L.; et al. A Non-Canonical Adenosinergic Pathway Led by CD38 in Human Melanoma Cells Induces Suppression of T Cell Proliferation. Oncotarget 2015, 6, 25602–25618. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  15. Park, J.; Gupta, R.S. Adenosine Kinase and Ribokinase—The RK Family of Proteins. Cell. Mol. Life Sci. 2008, 65, 2875–2896. [Google Scholar] [CrossRef] [PubMed]
  16. Bagheri, S.; Saboury, A.A.; Haertlé, T. Adenosine Deaminase Inhibition. Int. J. Biol. Macromol. 2019, 141, 1246–1257. [Google Scholar] [CrossRef] [PubMed]
  17. Park, J.; Gupta, R.S. Adenosine Metabolism, Adenosine Kinase, and Evolution. In Adenosine; Masino, S., Boison, D., Eds.; Springer: New York, NY, USA, 2013; pp. 23–54. [Google Scholar] [CrossRef]
  18. dos Santos-Rodrigues, A.; Grañé-Boladeras, N.; Bicket, A.; Coe, I.R. Nucleoside Transporters in the Purinome. Neurochem. Int. 2014, 73, 229–237. [Google Scholar] [CrossRef]
  19. Hajizadeh, F.; Okoye, I.; Esmaily, M.; Ghasemi Chaleshtari, M.; Masjedi, A.; Azizi, G.; Irandoust, M.; Ghalamfarsa, G.; Jadidi-Niaragh, F. Hypoxia Inducible Factors in the Tumor Microenvironment as Therapeutic Targets of Cancer Stem Cells. Life Sci. 2019, 237, 116952. [Google Scholar] [CrossRef]
  20. Spychala, J.; Kitajewski, J. Wnt and β-Catenin Signaling Target the Expression of Ecto-5′-Nucleotidase and Increase Extracellular Adenosine Generation. Exp. Cell Res. 2004, 296, 99–108. [Google Scholar] [CrossRef]
  21. Niemelä, J.; Henttinen, T.; Yegutkin, G.G.; Airas, L.; Kujari, A.-M.; Rajala, P.; Jalkanen, S. IFN-α Induced Adenosine Production on the Endothelium: A Mechanism Mediated by CD73 (Ecto-5′-Nucleotidase) Up-Regulation. J. Immunol. 2004, 172, 1646–1653. [Google Scholar] [CrossRef]
  22. Schuler, P.J.; Saze, Z.; Hong, C.-S.; Muller, L.; Gillespie, D.G.; Cheng, D.; Harasymczuk, M.; Mandapathil, M.; Lang, S.; Jackson, E.K.; et al. Human CD4+CD39+ Regulatory T Cells Produce Adenosine upon Co-Expression of Surface CD73 or Contact with CD73+ Exosomes or CD73+ Cells. Clin. Exp. Immunol. 2014, 177, 531–543. [Google Scholar] [CrossRef] [PubMed]
  23. Ohta, A. A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment. Front. Immunol. 2016, 7, 109. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Raskovalova, T.; Lokshin, A.; Huang, X.; Jackson, E.K.; Gorelik, E. Adenosine-Mediated Inhibition of Cytotoxic Activity and Cytokine Production by IL-2/NKp46-Activated NK Cells: Involvement of Protein Kinase A Isozyme I (PKA I). Immunol. Res. 2006, 36, 91–100. [Google Scholar] [CrossRef]
  25. Häusler, S.F.M.; Montalbán del Barrio, I.; Strohschein, J.; Anoop Chandran, P.; Engel, J.B.; Hönig, A.; Ossadnik, M.; Horn, E.; Fischer, B.; Krockenberger, M.; et al. Ectonucleotidases CD39 and CD73 on OvCA Cells Are Potent Adenosine-Generating Enzymes Responsible for Adenosine Receptor 2A-Dependent Suppression of T Cell Function and NK Cell Cytotoxicity. Cancer Immunol. Immunother. 2011, 60, 1405–1418. [Google Scholar] [CrossRef]
  26. Raskovalova, T.; Lokshin, A.; Huang, X.; Su, Y.; Mandic, M.; Zarour, H.M.; Jackson, E.K.; Gorelik, E. Inhibition of Cytokine Production and Cytotoxic Activity of Human Antimelanoma Specific CD8+ and CD4+ T Lymphocytes by Adenosine-Protein Kinase A Type I Signaling. Cancer Res. 2007, 67, 5949–5956. [Google Scholar] [CrossRef] [Green Version]
  27. Ma, S.-R.; Deng, W.-W.; Liu, J.-F.; Mao, L.; Yu, G.-T.; Bu, L.-L.; Kulkarni, A.B.; Zhang, W.-F.; Sun, Z.-J. Blockade of Adenosine A2A Receptor Enhances CD8+ T Cells Response and Decreases Regulatory T Cells in Head and Neck Squamous Cell Carcinoma. Mol. Cancer 2017, 16, 99. [Google Scholar] [CrossRef]
  28. Mediavilla-Varela, M.; Luddy, K.; Noyes, D.; Khalil, F.K.; Neuger, A.M.; Soliman, H.; Antonia, S.J. Antagonism of Adenosine A2A Receptor Expressed by Lung Adenocarcinoma Tumor Cells and Cancer Associated Fibroblasts Inhibits Their Growth. Cancer Biol. Ther. 2013, 14, 860–868. [Google Scholar] [CrossRef] [Green Version]
  29. Cekic, C.; Day, Y.-J.; Sag, D.; Linden, J. Myeloid Expression of Adenosine A2A Receptor Suppresses T and NK Cell Responses in the Solid Tumor Microenvironment. Cancer Res. 2014, 74, 7250–7259. [Google Scholar] [CrossRef] [Green Version]
  30. Ohta, A.; Kini, R.; Ohta, A.; Subramanian, M.; Madasu, M.; Sitkovsky, M. The Development and Immunosuppressive Functions of CD4+ CD25+ FoxP3+ Regulatory T Cells Are under Influence of the Adenosine-A2A Adenosine Receptor Pathway. Front. Immunol. 2012, 3, 190. [Google Scholar] [CrossRef] [Green Version]
  31. Sorrentino, C.; Miele, L.; Porta, A.; Pinto, A.; Morello, S. Myeloid-Derived Suppressor Cells Contribute to A2B Adenosine Receptor-Induced VEGF Production and Angiogenesis in a Mouse Melanoma Model. Oncotarget 2015, 6, 27478–27489. [Google Scholar] [CrossRef] [Green Version]
  32. Vaupel, P.; Mayer, A. Hypoxia-Driven Adenosine Accumulation: A Crucial Microenvironmental Factor Promoting Tumor Progression. In Oxygen Transport to Tissue XXXVII; Elwell, C.E., Leung, T.S., Harrison, D.K., Eds.; Advances in Experimental Medicine and Biology; Springer: New York, NY, USA, 2016; Volume 876, pp. 177–183. [Google Scholar] [CrossRef]
  33. Mittal, D.; Sinha, D.; Barkauskas, D.; Young, A.; Kalimutho, M.; Stannard, K.; Caramia, F.; Haibe-Kains, B.; Stagg, J.; Khanna, K.K.; et al. Adenosine 2B Receptor Expression on Cancer Cells Promotes Metastasis. Cancer Res. 2016, 76, 4372–4382. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Gessi, S.; Bencivenni, S.; Battistello, E.; Vincenzi, F.; Colotta, V.; Catarzi, D.; Varano, F.; Merighi, S.; Borea, P.A.; Varani, K. Inhibition of A2A Adenosine Receptor Signaling in Cancer Cells Proliferation by the Novel Antagonist TP455. Front. Pharmacol. 2017, 8, 888. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Zhou, Y.; Chu, X.; Deng, F.; Tong, L.; Tong, G.; Yi, Y.; Liu, J.; Tang, J.; Tang, Y.; Xia, Y.; et al. The Adenosine A2b Receptor Promotes Tumor Progression of Bladder Urothelial Carcinoma by Enhancing MAPK Signaling Pathway. Oncotarget 2017, 8, 48755–48768. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. Yu, M.; Guo, G.; Huang, L.; Deng, L.; Chang, C.-S.; Achyut, B.R.; Canning, M.; Xu, N.; Arbab, A.S.; Bollag, R.J.; et al. CD73 on Cancer-Associated Fibroblasts Enhanced by the A2B-Mediated Feedforward Circuit Enforces an Immune Checkpoint. Nat Commun. 2020, 11, 515. [Google Scholar] [CrossRef] [PubMed]
  37. Mazziotta, C.; Rotondo, J.C.; Lanzillotti, C.; Campione, G.; Martini, F.; Tognon, M. Cancer Biology and Molecular Genetics of A3 Adenosine Receptor. Oncogene 2022, 41, 301–308. [Google Scholar] [CrossRef]
  38. Novitskiy, S.V.; Ryzhov, S.; Zaynagetdinov, R.; Goldstein, A.E.; Huang, Y.; Tikhomirov, O.Y.; Blackburn, M.R.; Biaggioni, I.; Carbone, D.P.; Feoktistov, I.; et al. Adenosine Receptors in Regulation of Dendritic Cell Differentiation and Function. Blood 2008, 112, 1822–1831. [Google Scholar] [CrossRef]
  39. Chen, S.; Akdemir, I.; Fan, J.; Linden, J.; Zhang, B.; Cekic, C. The Expression of Adenosine A2B Receptor on Antigen-Presenting Cells Suppresses CD8+ T-Cell Responses and Promotes Tumor Growth. Cancer Immunol. Res. 2020, 8, 1064–1074. [Google Scholar] [CrossRef]
  40. Boison, D. Adenosine Kinase: Exploitation for Therapeutic Gain. Pharmacol. Rev. 2013, 65, 906–943. [Google Scholar] [CrossRef] [Green Version]
  41. Murugan, M.; Fedele, D.; Millner, D.; Alharfoush, E.; Vegunta, G.; Boison, D. Adenosine Kinase: An Epigenetic Modulator in Development and Disease. Neurochem. Int. 2021, 147, 105054. [Google Scholar] [CrossRef]
  42. Boison, D.; Scheurer, L.; Zumsteg, V.; Rulicke, T.; Litynski, P.; Fowler, B.; Brandner, S.; Mohler, H. Neonatal Hepatic Steatosis by Disruption of the Adenosine Kinase Gene. Proc. Natl. Acad. Sci. USA 2002, 99, 6985–6990. [Google Scholar] [CrossRef] [Green Version]
  43. Bjursell, M.K.; Blom, H.J.; Cayuela, J.A.; Engvall, M.L.; Lesko, N.; Balasubramaniam, S.; Brandberg, G.; Halldin, M.; Falkenberg, M.; Jakobs, C.; et al. Adenosine Kinase Deficiency Disrupts the Methionine Cycle and Causes Hypermethioninemia, Encephalopathy, and Abnormal Liver Function. Am. J. Hum. Genet. 2011, 89, 507–515. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Staufner, C.; Lindner, M.; Dionisi-Vici, C.; Freisinger, P.; Dobbelaere, D.; Douillard, C.; Makhseed, N.; Straub, B.K.; Kahrizi, K.; Ballhausen, D.; et al. Adenosine Kinase Deficiency: Expanding the Clinical Spectrum and Evaluating Therapeutic Options. J. Inherit. Metab. Dis. 2016, 39, 273–283. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Weltha, L.; Reemmer, J.; Boison, D. The Role of Adenosine in Epilepsy. Brain Res. Bull. 2019, 151, 46–54. [Google Scholar] [CrossRef] [PubMed]
  46. Greenberg, M.V.C.; Bourc’his, D. The Diverse Roles of DNA Methylation in Mammalian Development and Disease. Nat. Rev. Mol. Cell Biol. 2019, 20, 590–607. [Google Scholar] [CrossRef]
  47. Sahin, B.; Kansy, J.W.; Nairn, A.C.; Spychala, J.; Ealick, S.E.; Fienberg, A.A.; Greene, R.W.; Bibb, J.A. Molecular Characterization of Recombinant Mouse Adenosine Kinase and Evaluation as a Target for Protein Phosphorylation: Recombinant Mouse AK as a Protein Phosphorylation Target. Eur. J. Biochem. 2004, 271, 3547–3555. [Google Scholar] [CrossRef]
  48. Cui, X.A.; Agarwal, T.; Singh, B.; Gupta, R.S. Molecular Characterization of Chinese Hamster Cells Mutants Affected in Adenosine Kinase and Showing Novel Genetic and Biochemical Characteristics. BMC Biochem. 2011, 12, 22. [Google Scholar] [CrossRef] [Green Version]
  49. Cui, X.A.; Singh, B.; Park, J.; Gupta, R.S. Subcellular Localization of Adenosine Kinase in Mammalian Cells: The Long Isoform of AdK Is Localized in the Nucleus. Biochem. Biophys. Res. Commun. 2009, 388, 46–50. [Google Scholar] [CrossRef]
  50. Williams-Karnesky, R.L.; Sandau, U.S.; Lusardi, T.A.; Lytle, N.K.; Farrell, J.M.; Pritchard, E.M.; Kaplan, D.L.; Boison, D. Epigenetic Changes Induced by Adenosine Augmentation Therapy Prevent Epileptogenesis. J. Clin. Investig. 2013, 123, 3552–3563. [Google Scholar] [CrossRef] [Green Version]
  51. Kiese, K.; Jablonski, J.; Boison, D.; Kobow, K. Dynamic Regulation of the Adenosine Kinase Gene during Early Postnatal Brain Development and Maturation. Front. Mol. Neurosci. 2016, 9, 99. [Google Scholar] [CrossRef] [Green Version]
  52. Gebril, H.M.; Rose, R.M.; Gesese, R.; Emond, M.P.; Huo, Y.; Aronica, E.; Boison, D. Adenosine Kinase Inhibition Promotes Proliferation of Neural Stem Cells after Traumatic Brain Injury. Brain Commun. 2020, 2, fcaa017. [Google Scholar] [CrossRef] [Green Version]
  53. Yang, Y.; Zhang, N.; Zhang, G.; Sauve, A.A. NRH Salvage and Conversion to NAD+ Requires NRH Kinase Activity by Adenosine Kinase. Nat. Metab. 2020, 2, 364–379. [Google Scholar] [CrossRef] [PubMed]
  54. Bjorness, T.; Greene, R. Adenosine and Sleep. Curr. Neuropharmacol. 2009, 7, 238–245. [Google Scholar] [CrossRef] [PubMed]
  55. Palchykova, S.; Winsky-Sommerer, R.; Shen, H.-Y.; Boison, D.; Gerling, A.; Tobler, I. Manipulation of Adenosine Kinase Affects Sleep Regulation in Mice. J. Neurosci. 2010, 30, 13157–13165. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  56. Bjorness, T.E.; Dale, N.; Mettlach, G.; Sonneborn, A.; Sahin, B.; Fienberg, A.A.; Yanagisawa, M.; Bibb, J.A.; Greene, R.W. An Adenosine-Mediated Glial-Neuronal Circuit for Homeostatic Sleep. J. Neurosci. 2016, 36, 3709–3721. [Google Scholar] [CrossRef]
  57. Li, T.; Ren, G.; Lusardi, T.; Wilz, A.; Lan, J.Q.; Iwasato, T.; Itohara, S.; Simon, R.P.; Boison, D. Adenosine Kinase Is a Target for the Prediction and Prevention of Epileptogenesis in Mice. J. Clin. Investig. 2008, 118, JCI33737. [Google Scholar] [CrossRef] [Green Version]
  58. Annes, J.P.; Ryu, J.H.; Lam, K.; Carolan, P.J.; Utz, K.; Hollister-Lock, J.; Arvanites, A.C.; Rubin, L.L.; Weir, G.; Melton, D.A. Adenosine Kinase Inhibition Selectively Promotes Rodent and Porcine Islet β-Cell Replication. Proc. Natl. Acad. Sci. USA 2012, 109, 3915–3920. [Google Scholar] [CrossRef] [Green Version]
  59. Navarro, G.; Abdolazimi, Y.; Zhao, Z.; Xu, H.; Lee, S.; Armstrong, N.A.; Annes, J.P. Genetic Disruption of Adenosine Kinase in Mouse Pancreatic β-Cells Protects Against High-Fat Diet–Induced Glucose Intolerance. Diabetes 2017, 66, 1928–1938. [Google Scholar] [CrossRef] [Green Version]
  60. Wang, Y.; Xu, Y.; Yan, S.; Cao, K.; Zeng, X.; Zhou, Y.; Liu, Z.; Yang, Q.; Pan, Y.; Wang, X.; et al. Adenosine Kinase Is Critical for Neointima Formation after Vascular Injury by Inducing Aberrant DNA Hypermethylation. Cardiovasc. Res. 2021, 117, 561–575. [Google Scholar] [CrossRef]
  61. Zhang, M.; Zeng, X.; Yang, Q.; Xu, J.; Liu, Z.; Zhou, Y.; Cao, Y.; Zhang, X.; An, X.; Xu, Y.; et al. Ablation of Myeloid ADK (Adenosine Kinase) Epigenetically Suppresses Atherosclerosis in ApoE−/− (Apolipoprotein E Deficient) Mice. Arter. Thromb. Vasc. Biol. 2018, 38, 2780–2792. [Google Scholar] [CrossRef] [Green Version]
  62. Shamloo, B.; Kumar, N.; Owen, R.H.; Reemmer, J.; Ost, J.; Perkins, R.S.; Shen, H.-Y. Dysregulation of Adenosine Kinase Isoforms in Breast Cancer. Oncotarget 2019, 10, 7238–7250. [Google Scholar] [CrossRef]
  63. Ohta, A.; Gorelik, E.; Prasad, S.J.; Ronchese, F.; Lukashev, D.; Wong, M.K.K.; Huang, X.; Caldwell, S.; Liu, K.; Smith, P.; et al. A2A Adenosine Receptor Protects Tumors from Antitumor T Cells. Proc. Natl. Acad. Sci. USA 2006, 103, 13132–13137. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  64. Sitkovsky, M.V.; Hatfield, S.; Abbott, R.; Belikoff, B.; Lukashev, D.; Ohta, A. Hostile, Hypoxia–A2-Adenosinergic Tumor Biology as the Next Barrier to Overcome for Tumor Immunologists. Cancer Immunol. Res. 2014, 2, 598–605. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  65. Giglioni, S.; Leoncini, R.; Aceto, E.; Chessa, A.; Civitelli, S.; Bernini, A.; Tanzini, G.; Carraro, F.; Pucci, A.; Vannoni, D. Adenosine Kinase Gene Expression in Human Colorectal Cancer. Nucleosides Nucleotides Nucleic Acids 2008, 27, 750–754. [Google Scholar] [CrossRef] [PubMed]
  66. Vannoni, D.; Bernini, A.; Carlucci, F.; Civitelli, S.; Di Pietro, M.C.; Leoncini, R.; Rosi, F.; Tabucchi, A.; Tanzini, G.; Marinello, E. Enzyme Activities Controlling Adenosine Levels in Normal and Neoplastic Tissues. Med. Oncol. 2004, 21, 187–196. [Google Scholar] [CrossRef]
  67. Huang, J.; He, Y.; Chen, M.; Du, J.; Li, G.; Li, S.; Liu, W.; Long, X. Adenosine Deaminase and Adenosine Kinase Expression in Human Glioma and Their Correlation with Glioma-Associated Epilepsy. Mol. Med. Rep. 2015, 12, 6509–6516. [Google Scholar] [CrossRef] [Green Version]
  68. El-Kharrag, R.; Owen, R.; Boison, D. Adenosine Kinase Deficiency Increases Susceptibility to a Carcinogen. J. Caffeine Adenosine Res. 2019, 9, 4–11. [Google Scholar] [CrossRef] [Green Version]
  69. Wahba, A.E.; Fedele, D.; Gebril, H.; AlHarfoush, E.; Toti, K.S.; Jacobson, K.A.; Boison, D. Adenosine Kinase Expression Determines DNA Methylation in Cancer Cell Lines. ACS Pharmacol. Transl. Sci. 2021, 4, 680–686. [Google Scholar] [CrossRef]
  70. Morote-Garcia, J.C.; Rosenberger, P.; Nivillac, N.M.I.; Coe, I.R.; Eltzschig, H.K. Hypoxia-Inducible Factor–Dependent Repression of Equilibrative Nucleoside Transporter 2 Attenuates Mucosal Inflammation During Intestinal Hypoxia. Gastroenterology 2009, 136, 607–618. [Google Scholar] [CrossRef]
  71. Xu, Y.; Wang, Y.; Yan, S.; Zhou, Y.; Yang, Q.; Pan, Y.; Zeng, X.; An, X.; Liu, Z.; Wang, L.; et al. Intracellular Adenosine Regulates Epigenetic Programming in Endothelial Cells to Promote Angiogenesis. EMBO Mol. Med. 2017, 9, 1263–1278. [Google Scholar] [CrossRef]
  72. Kaljas, Y.; Liu, C.; Skaldin, M.; Wu, C.; Zhou, Q.; Lu, Y.; Aksentijevich, I.; Zavialov, A.V. Human Adenosine Deaminases ADA1 and ADA2 Bind to Different Subsets of Immune Cells. Cell. Mol. Life Sci. 2017, 74, 555–570. [Google Scholar] [CrossRef]
  73. Meyts, I.; Aksentijevich, I. Deficiency of Adenosine Deaminase 2 (DADA2): Updates on the Phenotype, Genetics, Pathogenesis, and Treatment. J. Clin. Immunol. 2018, 38, 569–578. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  74. Moreno, E.; Canet, J.; Gracia, E.; Lluís, C.; Mallol, J.; Canela, E.I.; Cortés, A.; Casadó, V. Molecular Evidence of Adenosine Deaminase Linking Adenosine A2A Receptor and CD26 Proteins. Front. Pharmacol. 2018, 9, 106. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  75. Pacheco, R.; Martinez-Navio, J.M.; Lejeune, M.; Climent, N.; Oliva, H.; Gatell, J.M.; Gallart, T.; Mallol, J.; Lluis, C.; Franco, R. CD26, Adenosine Deaminase, and Adenosine Receptors Mediate Costimulatory Signals in the Immunological Synapse. Proc. Natl. Acad. Sci. USA 2005, 102, 9583–9588. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  76. Ginés, S.; Mariño, M.; Mallol, J.; Canela, E.I.; Morimoto, C.; Callebaut, C.; Hovanessian, A.; Casadó, V.; Lluis, C.; Franco, R. Regulation of Epithelial and Lymphocyte Cell Adhesion by Adenosine Deaminase–CD26 Interaction. Biochem. J. 2002, 361, 203–209. [Google Scholar] [CrossRef]
  77. Mandapathil, M.; Szczepanski, M.; Harasymczuk, M.; Ren, J.; Cheng, D.; Jackson, E.K.; Gorelik, E.; Johnson, J.; Lang, S.; Whiteside, T.L. CD26 Expression and Adenosine Deaminase Activity in Regulatory T Cells (Treg) and CD4+ T Effector Cells in Patients with Head and Neck Squamous Cell Carcinoma. OncoImmunology 2012, 1, 659–669. [Google Scholar] [CrossRef] [Green Version]
  78. Naval-Macabuhay, I.; Casanova, V.; Navarro, G.; García, F.; León, A.; Miralles, L.; Rovira, C.; Martinez-Navio, J.M.; Gallart, T.; Mallol, J.; et al. Adenosine Deaminase Regulates Treg Expression in Autologous T Cell-Dendritic Cell Cocultures from Patients Infected with HIV-1. J. Leukoc. Biol. 2016, 99, 349–359. [Google Scholar] [CrossRef] [Green Version]
  79. Tardif, V.; Muir, R.; Cubas, R.; Chakhtoura, M.; Wilkinson, P.; Metcalf, T.; Herro, R.; Haddad, E.K. Adenosine Deaminase-1 Delineates Human Follicular Helper T Cell Function and Is Altered with HIV. Nat. Commun. 2019, 10, 823. [Google Scholar] [CrossRef]
  80. Zavialov, A.V.; Yu, X.; Spillmann, D.; Lauvau, G.; Zavialov, A.V. Structural Basis for the Growth Factor Activity of Human Adenosine Deaminase ADA2. J. Biol. Chem. 2010, 285, 12367–12377. [Google Scholar] [CrossRef] [Green Version]
  81. Zavialov, A.V.; Gracia, E.; Glaichenhaus, N.; Franco, R.; Zavialov, A.V.; Lauvau, G. Human Adenosine Deaminase 2 Induces Differentiation of Monocytes into Macrophages and Stimulates Proliferation of T Helper Cells and Macrophages. J. Leukoc. Biol. 2010, 88, 279–290. [Google Scholar] [CrossRef]
  82. Valdés, L.; San José, E.; Alvarez, D.; Valle, J.M. Adenosine Deaminase (ADA) Isoenzyme Analysis in Pleural Effusions: Diagnostic Role, and Relevance to the Origin of Increased ADA in Tuberculous Pleurisy. Eur. Respir. J. 1996, 9, 747–751. [Google Scholar] [CrossRef] [Green Version]
  83. Tsuboi, I.; Sagawa, K.; Shichijo, S.; Yokoyama, M.M.; Ou, D.W.; Wiederhold, M.D. Adenosine Deaminase Isoenzyme Levels in Patients with Human T-Cell Lymphotropic Virus Type 1 and Human Immunodeficiency Virus Type 1 Infections. Clin. Diagn. Lab. Immunol. 1995, 2, 626–630. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  84. Hitoglou, S.; Hatzistilianou, M.; Gougoustamou, D.; Athanassiadou, F.; Kotsis, A.; Catriu, D. Adenosine Deaminase Activity and Its Isoenzyme Pattern in Patients with Juvenile Rheumatoid Arthritis and Systemic Lupus Erythematosus. Clin. Rheumatol. 2001, 20, 411–416. [Google Scholar] [CrossRef] [PubMed]
  85. Delemarre, E.M.; van Hoorn, L.; Bossink, A.W.J.; Drylewicz, J.; Joosten, S.A.; Ottenhoff, T.H.M.; Akkerman, O.W.; Goletti, D.; Petruccioli, E.; Navarra, A.; et al. Serum Biomarker Profile Including CCL1, CXCL10, VEGF, and Adenosine Deaminase Activity Distinguishes Active from Remotely Acquired Latent Tuberculosis. Front. Immunol. 2021, 12, 725447. [Google Scholar] [CrossRef] [PubMed]
  86. Zavialov, A.V.; Engström, Å. Human ADA2 Belongs to a New Family of Growth Factors with Adenosine Deaminase Activity. Biochem. J. 2005, 391, 51–57. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  87. Caorsi, R.; Penco, F.; Schena, F.; Gattorno, M. Monogenic Polyarteritis: The Lesson of ADA2 Deficiency. Pediatr. Rheumatol. 2016, 14, 51. [Google Scholar] [CrossRef] [Green Version]
  88. Zhou, Q.; Yang, D.; Ombrello, A.K.; Zavialov, A.V.; Toro, C.; Zavialov, A.V.; Stone, D.L.; Chae, J.J.; Rosenzweig, S.D.; Bishop, K.; et al. Early-Onset Stroke and Vasculopathy Associated with Mutations in ADA2. N. Engl. J. Med. 2014, 370, 911–920. [Google Scholar] [CrossRef] [Green Version]
  89. Navon Elkan, P.; Pierce, S.B.; Segel, R.; Walsh, T.; Barash, J.; Padeh, S.; Zlotogorski, A.; Berkun, Y.; Press, J.J.; Mukamel, M.; et al. Mutant Adenosine Deaminase 2 in a Polyarteritis Nodosa Vasculopathy. N. Engl. J. Med. 2014, 370, 921–931. [Google Scholar] [CrossRef]
  90. Gaspar, H.B.; Aiuti, A.; Porta, F.; Candotti, F.; Hershfield, M.S.; Notarangelo, L.D. How I Treat ADA Deficiency. Blood 2009, 114, 3524–3532. [Google Scholar] [CrossRef] [Green Version]
  91. Rostampour, F.; Biglari, M.; Vaisi-Raygani, A.; Salimi, S.; Tavilani, H. Adenosine Deaminase Activity in Fertile and Infertile Men: Adenosine Deaminase and Male Infertility. Andrologia 2012, 44, 586–589. [Google Scholar] [CrossRef]
  92. Fattahi, A.; Khodadadi, I.; Amiri, I.; Latifi, Z.; Ghorbani, M.; Tavilani, H. The Role of G22 A Adenosine Deaminase 1 Gene Polymorphism and the Activities of ADA Isoenzymes in Fertile and Infertile Men. Urology 2015, 86, 730–734. [Google Scholar] [CrossRef]
  93. Odumade, O.A.; Plotkin, A.L.; Pak, J.; Idoko, O.T.; Pettengill, M.A.; Kollmann, T.R.; Ozonoff, A.; Kampmann, B.; Levy, O.; Smolen, K.K. Plasma Adenosine Deaminase (ADA)-1 and -2 Demonstrate Robust Ontogeny Across the First Four Months of Human Life. Front. Immunol. 2021, 12, 578700. [Google Scholar] [CrossRef] [PubMed]
  94. Bowers, S.M.; Gibson, K.M.; Cabral, D.A.; Brown, K.L. Adenosine Deaminase 2 Activity Negatively Correlates with Age during Childhood. Pediatr. Rheumatol. 2020, 18, 54. [Google Scholar] [CrossRef] [PubMed]
  95. Durak, I.; Cetin, R.; Canbolat, O.; Cetin, D.; Yurtarslani, Z.; Ünal, A. Adenosine Deaminase, 5′-Nucleotidase, Guanase and Cytidine Deaminase Activities in Gastric Tissues from Patients with Gastric Cancer. Cancer Lett. 1994, 84, 199–202. [Google Scholar] [CrossRef]
  96. Durak, I.; Örmeci, N.; Akyol, Ö.; Canbolat, O.; Kavutçu, M.; Bülbül, M. Adenosine Deaminase, 5′-Nucleotidase, Xanthine Oxidase, Superoxide Dismutase, and Catalase Activities in Gastric Juices from Patients with Gastric Cancer, Ulcer, and Atrophic Gastritis. Digest. Dis. Sci. 1994, 39, 721–728. [Google Scholar] [CrossRef]
  97. Pirinççi, N.; Geçit, I.; Güneş, M.; Yuksel, M.; Kaba, M.; Tanık, S.; Demir, H.; Aslan, M. Serum Adenosine Deaminase, Catalase and Carbonic Anhydrase Activities in Patients with Bladder Cancer. Clinics 2012, 67, 1443–1446. [Google Scholar] [CrossRef]
  98. Durak, İ.; Perk, H.; Kavutçu, M.; Canbolat, O.; Akyol, Ö.; Bedük, Y. Adenosine Deaminase, 5′nucleotidase, Xanthine Oxidase, Superoxide Dismutase, and Catalase Activities in Cancerous and Noncancerous Human Bladder Tissues. Free. Radic. Biol. Med. 1994, 16, 825–831. [Google Scholar] [CrossRef]
  99. Faisal, A.; Taha, M. Serum Adenosine Deaminase Activity in Iraqi Patients with Breast Cancer on Tamoxifen Therapy. Gaziantep Med. J. 2012, 18, 139. [Google Scholar] [CrossRef] [Green Version]
  100. Aghaei, M.; Karami-Tehrani, F.; Salami, S.; Atri, M. Diagnostic Value of Adenosine Deaminase Activity in Benign and Malignant Breast Tumors. Arch. Med. Res. 2010, 41, 14–18. [Google Scholar] [CrossRef]
  101. Pirinççi, N.; Kaya, T.Y.; Kaba, M.; Ozan, T.; Geçit, İ.; Özveren, H.; Eren, H.; Ceylan, K. Serum Adenosine Deaminase, Catalase, and Carbonic Anhydrase Activities in Patients with Renal Cell Carcinoma. Redox Rep. 2017, 22, 252–256. [Google Scholar] [CrossRef] [Green Version]
  102. Kutryb-Zajac, B.; Harasim, G.; Jedrzejewska, A.; Krol, O.; Braczko, A.; Jablonska, P.; Mierzejewska, P.; Zielinski, J.; Slominska, E.M.; Smolenski, R.T. Macrophage-Derived Adenosine Deaminase 2 Correlates with M2 Macrophage Phenotype in Triple Negative Breast Cancer. Int. J. Mol. Sci. 2021, 22, 3764. [Google Scholar] [CrossRef]
  103. Battisti, V.; Maders, L.D.K.; Bagatini, M.D.; Battisti, I.E.; Bellé, L.P.; Santos, K.F.; Maldonado, P.A.; Thomé, G.R.; Schetinger, M.R.C.; Morsch, V.M. Ectonucleotide Pyrophosphatase/Phosphodiesterase (E-NPP) and Adenosine Deaminase (ADA) Activities in Prostate Cancer Patients: Influence of Gleason Score, Treatment and Bone Metastasis. Biomed. Pharmacother. 2013, 67, 203–208. [Google Scholar] [CrossRef] [PubMed]
  104. Durak, İ.; Işik, C.Ü.; Canbolat, O.; Akyol, Ö.; Kavutçu, M. Adenosine Deaminase, 5′ Nucleotidase, Xanthine Oxidase, Superoxide Dismutase, and Catalase Activities in Cancerous and Noncancerous Human Laryngeal Tissues. Free. Radic. Biol. Med. 1993, 15, 681–684. [Google Scholar] [CrossRef]
  105. Theodoraki, M.-N.; Hoffmann, T.K.; Jackson, E.K.; Whiteside, T.L. Exosomes in HNSCC Plasma as Surrogate Markers of Tumour Progression and Immune Competence. Clin. Exp. Immunol. 2018, 194, 67–78. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  106. Zanini, D.; Manfredi, L.H.; Pelinson, L.P.; Pimentel, V.C.; Cardoso, A.M.; do Carmo Araújo Gonçalves, V.; dos Santos, C.B.; Gutierres, J.M.; Morsch, V.M.; Leal, D.B.R.; et al. ADA Activity Is Decreased in Lymphocytes from Patients with Advanced Stage of Lung Cancer. Med. Oncol. 2019, 36, 78. [Google Scholar] [CrossRef]
  107. Hocanlı, İ.; Uzer, F.; Çil, B.; Kırhan, İ.; Günak, F. Diagnostic Value of Adenosine Deaminase in Bronchoalveolar Lavage Fluid for Patients with Lung Cancer. Int. J. Clin. Pract. 2021, 75, e14918. [Google Scholar] [CrossRef]
  108. Wang, T.; Gnanaprakasam, J.N.R.; Chen, X.; Kang, S.; Xu, X.; Sun, H.; Liu, L.; Rodgers, H.; Miller, E.; Cassel, T.A.; et al. Inosine Is an Alternative Carbon Source for CD8+-T-Cell Function under Glucose Restriction. Nat. Metab. 2020, 2, 635–647. [Google Scholar] [CrossRef]
  109. Wang, L.; Londono, L.M.; Cowell, J.; Saatci, O.; Aras, M.; Ersan, P.G.; Serra, S.; Pei, H.; Clift, R.; Zhao, Q.; et al. Targeting Adenosine with Adenosine Deaminase 2 to Inhibit Growth of Solid Tumors. Cancer Res. 2021, 81, 3319–3332. [Google Scholar] [CrossRef]
  110. Qu, Y.; Dunn, Z.S.; Chen, X.; MacMullan, M.; Cinay, G.; Wang, H.; Liu, J.; Hu, F.; Wang, P. Adenosine Deaminase 1 Overexpression Enhances the Antitumor Efficacy of Chimeric Antigen Receptor-Engineered T Cells. Hum. Gene Ther. 2021. [Google Scholar] [CrossRef]
  111. Kreitman, R.J. Hairy Cell Leukemia: Present and Future Directions. Leuk. Lymphoma 2019, 60, 2869–2879. [Google Scholar] [CrossRef]
  112. Nakajima, Y.; Kanno, T.; Nagaya, T.; Kuribayashi, K.; Nakano, T.; Gotoh, A.; Nishizaki, T. Adenosine Deaminase Inhibitor EHNA Exhibits a Potent Anticancer Effect Against Malignant Pleural Mesothelioma. Cell. Physiol. Biochem. 2015, 35, 51–60. [Google Scholar] [CrossRef]
  113. Kutryb-Zajac, B.; Koszalka, P.; Mierzejewska, P.; Bulinska, A.; Zabielska, M.A.; Brodzik, K.; Skrzypkowska, A.; Zelazek, L.; Pelikant-Malecka, I.; Slominska, E.M.; et al. Adenosine Deaminase Inhibition Suppresses Progression of 4T1 Murine Breast Cancer by Adenosine Receptor-Dependent Mechanisms. J. Cell. Mol. Med. 2018, 22, 5939–5954. [Google Scholar] [CrossRef]
  114. Boison, D.; Jarvis, M.F. Adenosine Kinase: A Key Regulator of Purinergic Physiology. Biochem. Pharmacol. 2021, 187, 114321. [Google Scholar] [CrossRef] [PubMed]
  115. Ahmed Abdalhamid Osman, M.; Sun, Y.; Li, R.; Lin, H.; Zeng, D.; Chen, X.; He, D.; Feng, H.; Yang, Z.; Wang, J.; et al. Deletion of Pancreatic Β-cell Adenosine Kinase Improves Glucose Homeostasis in Young Mice and Ameliorates Streptozotocin-induced Hyperglycaemia. J. Cell. Mol. Med. 2019, 23, 4653–4665. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  116. Gokul, G.; Khosla, S. DNA Methylation and Cancer. In Epigenetics: Development and Disease; Kundu, T.K., Ed.; Subcellular Biochemistry; Springer: Dordrecht, The Netherlands, 2013; Volume 61, pp. 597–625. [Google Scholar] [CrossRef]
  117. Mohammad, H.P.; Barbash, O.; Creasy, C.L. Targeting Epigenetic Modifications in Cancer Therapy: Erasing the Roadmap to Cancer. Nat. Med. 2019, 25, 403–418. [Google Scholar] [CrossRef] [PubMed]
  118. Pignataro, G.; Simon, R.P.; Boison, D. Transgenic Overexpression of Adenosine Kinase Aggravates Cell Death in Ischemia. J. Cereb. Blood Flow Metab. 2007, 27, 1–5. [Google Scholar] [CrossRef]
  119. Zhulai, G.; Oleinik, E. Targeting Regulatory T Cells in Anti-PD-1/PD-L1 Cancer Immunotherapy. Scand. J. Immunol. 2022, 95, e13129. [Google Scholar] [CrossRef]
  120. Iannone, R.; Miele, L.; Maiolino, P.; Pinto, A.; Morello, S. Adenosine Limits the Therapeutic Effectiveness of Anti-CTLA4 MAb in a Mouse Melanoma Model. Am. J. Cancer Res. 2014, 4, 172–181. [Google Scholar]
  121. Beavis, P.A.; Henderson, M.A.; Giuffrida, L.; Mills, J.K.; Sek, K.; Cross, R.S.; Davenport, A.J.; John, L.B.; Mardiana, S.; Slaney, C.Y.; et al. Targeting the Adenosine 2A Receptor Enhances Chimeric Antigen Receptor T Cell Efficacy. J. Clin. Investig. 2017, 127, 929–941. [Google Scholar] [CrossRef] [Green Version]
  122. Leone, R.D.; Sun, I.-M.; Oh, M.-H.; Sun, I.-H.; Wen, J.; Englert, J.; Powell, J.D. Inhibition of the Adenosine A2a Receptor Modulates Expression of T Cell Coinhibitory Receptors and Improves Effector Function for Enhanced Checkpoint Blockade and ACT in Murine Cancer Models. Cancer Immunol. Immunother. 2018, 67, 1271–1284. [Google Scholar] [CrossRef]
  123. Yang, R.; Elsaadi, S.; Misund, K.; Abdollahi, P.; Vandsemb, E.N.; Moen, S.H.; Kusnierczyk, A.; Slupphaug, G.; Standal, T.; Waage, A.; et al. Conversion of ATP to Adenosine by CD39 and CD73 in Multiple Myeloma Can Be Successfully Targeted Together with Adenosine Receptor A2A Blockade. J. Immunother. Cancer 2020, 8, e000610. [Google Scholar] [CrossRef]
  124. Yan, J.; Li, X.-Y.; Roman Aguilera, A.; Xiao, C.; Jacoberger-Foissac, C.; Nowlan, B.; Robson, S.C.; Beers, C.; Moesta, A.K.; Geetha, N.; et al. Control of Metastases via Myeloid CD39 and NK Cell Effector Function. Cancer Immunol. Res. 2020, 8, 356–367. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  125. Young, A.; Ngiow, S.F.; Barkauskas, D.S.; Sult, E.; Hay, C.; Blake, S.J.; Huang, Q.; Liu, J.; Takeda, K.; Teng, M.W.L.; et al. Co-Inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-Tumor Immune Responses. Cancer Cell 2016, 30, 391–403. [Google Scholar] [CrossRef] [PubMed] [Green Version]
Biomolecules 12 00418 g001 550
Figure 1. Adenosine metabolism. The canonical pathway of adenosine synthesis involves the hydrolysis of ATP to AMP by ecto-nucleoside triphosphate diphosphohydrolase (NTPDase1, CD39) and the hydrolysis of AMP by ecto-5′-nucleotidase (5′NT, CD73). The non-canonical pathway involves the use of NAD+ as a substrate by CD38 or CD157 to generate ADP-ribose (ADPR) directly or through its cyclic form (cADPR). ADPR is then processed to AMP by CD203a (Ectonucleotide Pyrophosphatase/Phosphodiesterase 1). Extracellular adenosine can bind to its receptors or be metabolized to inosine by ecto-adenosine deaminase (ecto-ADA). Adenosine is transported into and out of the cell by concentrative or equilibrative nucleoside transporters (NTs). Intracellular adenosine synthesis is controlled by the balance of the activity of enzymes: adenosine kinase (ADK), cytoplasmic 5′nucleotidase (Cyto-5′NT), adenosine deaminase (ADA). Adenosine is generated as an end product in the transmethylation reaction: transmethylation reactions include the transfer of methyl groups from S-adenosylmethionine (SAM) to a wide range of acceptors. The resulting product, S-adenosylhomocysteine (SAH), is then cleaved by SAH hydrolase (SAHH) into adenosine and homocysteine.
Figure 1. Adenosine metabolism. The canonical pathway of adenosine synthesis involves the hydrolysis of ATP to AMP by ecto-nucleoside triphosphate diphosphohydrolase (NTPDase1, CD39) and the hydrolysis of AMP by ecto-5′-nucleotidase (5′NT, CD73). The non-canonical pathway involves the use of NAD+ as a substrate by CD38 or CD157 to generate ADP-ribose (ADPR) directly or through its cyclic form (cADPR). ADPR is then processed to AMP by CD203a (Ectonucleotide Pyrophosphatase/Phosphodiesterase 1). Extracellular adenosine can bind to its receptors or be metabolized to inosine by ecto-adenosine deaminase (ecto-ADA). Adenosine is transported into and out of the cell by concentrative or equilibrative nucleoside transporters (NTs). Intracellular adenosine synthesis is controlled by the balance of the activity of enzymes: adenosine kinase (ADK), cytoplasmic 5′nucleotidase (Cyto-5′NT), adenosine deaminase (ADA). Adenosine is generated as an end product in the transmethylation reaction: transmethylation reactions include the transfer of methyl groups from S-adenosylmethionine (SAM) to a wide range of acceptors. The resulting product, S-adenosylhomocysteine (SAH), is then cleaved by SAH hydrolase (SAHH) into adenosine and homocysteine.
Biomolecules 12 00418 g001
Biomolecules 12 00418 g002 550
Figure 2. The effect of adenosine on tumor-infiltrating cells. Adenosine can bind to four different G-protein-coupled adenosine receptors that either stimulate (mediated by A2A and A2B adenosine receptors) or inhibit (mediated by A1 and A3 adenosine receptors) adenylate cyclase activity and cAMP production in the cell. Activation of adenosine receptors on various types of cells in the tumor microenvironment can lead to the formation of immunosuppressive conditions and inhibition of the anti-tumor immune response. Abbreviations: ATP: adenosine triphosphate; cAMP: cyclic adenosine monophosphate; Treg: regulatory T cells; Foxp3: forkhead box P3; APCs: antigen-presenting cells; MDSCs: myeloid-derived suppressor cells; VEGF: vascular endothelial growth factor; bFGF: basic fibroblast growth factor.
Figure 2. The effect of adenosine on tumor-infiltrating cells. Adenosine can bind to four different G-protein-coupled adenosine receptors that either stimulate (mediated by A2A and A2B adenosine receptors) or inhibit (mediated by A1 and A3 adenosine receptors) adenylate cyclase activity and cAMP production in the cell. Activation of adenosine receptors on various types of cells in the tumor microenvironment can lead to the formation of immunosuppressive conditions and inhibition of the anti-tumor immune response. Abbreviations: ATP: adenosine triphosphate; cAMP: cyclic adenosine monophosphate; Treg: regulatory T cells; Foxp3: forkhead box P3; APCs: antigen-presenting cells; MDSCs: myeloid-derived suppressor cells; VEGF: vascular endothelial growth factor; bFGF: basic fibroblast growth factor.
Biomolecules 12 00418 g002
Biomolecules 12 00418 g003 550
Figure 3. Targeting adenosine in cancer therapy. Possible adenosine-associated targets for cancer therapy. Signaling, and extracellular and intracellular metabolism may be involved in limiting the immunosuppressive action of adenosine. Possible therapeutic targets are A2A receptors (A2AR) on T cells, and A2B and A3 receptors on tumor cells. Like a part of the extracellular metabolism, the CD39-CD73 axis and the CD38/CD157-CD203a-CD73 axis are actively investigated in clinical trials. Targeting adenosine-cleaving enzymes, ADK and ADA, as well as nucleotide transporters, may become a new direction in cancer therapy. Of particular interest is ADK-L, which is involved in epigenetic regulation.
Figure 3. Targeting adenosine in cancer therapy. Possible adenosine-associated targets for cancer therapy. Signaling, and extracellular and intracellular metabolism may be involved in limiting the immunosuppressive action of adenosine. Possible therapeutic targets are A2A receptors (A2AR) on T cells, and A2B and A3 receptors on tumor cells. Like a part of the extracellular metabolism, the CD39-CD73 axis and the CD38/CD157-CD203a-CD73 axis are actively investigated in clinical trials. Targeting adenosine-cleaving enzymes, ADK and ADA, as well as nucleotide transporters, may become a new direction in cancer therapy. Of particular interest is ADK-L, which is involved in epigenetic regulation.
Biomolecules 12 00418 g003
Table
Table 1. Characteristics of ADK isoforms and ADA isoforms *.
Table 1. Characteristics of ADK isoforms and ADA isoforms *.
ADKADA
ADK-L
(Isoform 1)		ADK-S
(Isoform 2)		ADA1ADA2
Gene
(chromosome)		ADK
(10q22.2)		ADA
20q13.12		ADA2
22q11.1
Protein structure40.5 kDa monomer, 362-amino acid formmonomer, 345-amino acid form40.8 kDa monomer, 363 amino acids59 kDa
monomer-homodimer, 511 amino acids
Tissue specificityWidely expressed, occurs in large amounts in liver, heart, kidney, lung, pancreas, and spleenWidely expressed, occurs in large amounts in liver, brain, kidney, lung, and pancreasFound in all tissues, occurs in large amounts in lymphocytes and intestineHuman adult heart, lung, lymphoblasts, and placenta, fetal lung, liver, and kidney
Cell specificityUbiquitously, neuronal cells, glial cellsUbiquitously, lymphocytes, erythrocytesMyeloid cells
Cellular localizationIntracellular, nucleusIntracellular, cytoplasm;
plasma membrane 		Intracellular;
extracellular via CD26		Extracellular, secreted;
lysosome
FunctionsCatalyzes the phosphorylation of adenosine to AMP;
Facilitates methylation reactions by the removal of adenosine, the end product of SAM-dependent transmethylation reactions		Catalyzes the phosphorylation of adenosine to AMP, using ATP as a phosphate donor and produces ADP and AMP;
Acts as a regulator of concentrations of extracellular adenosine and intracellular adenine nucleotides		Catalyzes the hydrolysis of adenosine to inosine and 2-deoxyadenosine to 2-deoxyinosine;
Acts as a positive regulator of T cell coactivation, by binding CD26;
Enhances DC immunogenicity;
Acts as a positive modulator of A1R and A2AR		May contribute to the degradation of extracellular adenosine
Binds to cell surfaces via proteoglycans and may play a role in the regulation of cell proliferation and differentiation, independently of its enzyme activity
Km for adenosineApprox. 1 µM-Approx. 37 µMApprox. 2.25 mM
Disease at deficiencyHypermethioninemia encephalopathy
due to adenosine kinase deficiency 		T-B-NK- severe combined immunodeficiencyADA2 deficiency
* Based on the GeneCards database and The Human Protein Atlas.
Table
Table 2. The role of ADK in carcinogenesis.
Table 2. The role of ADK in carcinogenesis.
Cancer/ModelParameterSignificanceRef.
PC3 human prostate carcinoma cell line and MDA-MB-231 human breast adenocarcinoma cellsProtein levelThe adenosine-ATP catalytic cascade is initiated via ADK-mediated phosphorylation of adenosine into AMP rather than its deamination to inosine [13]
Breast cancer (n = 46 patients) and breast cancer MDA-MB-231 cell lineProtein levelADK-L expression was significantly increased in breast cancer tissue; ADK downregulation suppressed proliferation, viability, migration, and invasion of cancer cells [62]
Colorectal cancer
(n = 10 patients)		Gene expressionADK expression is higher in tumor than in healthy tissue [65]
Colorectal cancer
(n = 40 patients)		Enzyme activityHigher in tumor than in healthy tissue (p < 0.01) [66]
Glioma (n = 45 patients)Gene and protein expression levelsIn tumoral and peritumoral tissues, ADK expression was markedly elevated compared with that in control tissues (p < 0.05) [67]
Liver cancer (n = 11 patients) and mouse model of hepatic ADK deficiencyProtein levelADK in the liver might play a role in determining the liver’s susceptibility to cancer development [68]
HeLa, HepG2, and U373 cancer cell linesProtein levelHeLa cells combine the highest DNA methylation levels with the highest expression levels of ADK-L; ADK inhibitors significantly reduced global DNA methylation in HeLa cells [69]
Table
Table 3. The role of ADA in carcinogenesis.
Table 3. The role of ADA in carcinogenesis.
Cancer/ModelParameterSignificanceRef.
Gastric cancer
(n = 15 patients)		Enzyme activityADA activity increased in the cancerous tissues (p < 0.0005); there were no significant differences between I-II stages and III-IV stages [95]
Gastric cancer
(n = 26 patients)		Enzyme activity and protein levelADA activity of the cancer gastric juices were lower (p < 0.01) and protein concentrations were higher than in the healthy control group [96]
Bladder cancer
(n = 40 patients)		Serum enzyme activityADA activity was significantly higher in cancer than in healthy controls [97]
Bladder cancer
(n = 36 patients)		Enzyme activityIncreased ADA activity was found in cancerous tissues compared with cancer-free adjacent tissues (p < 0.05) [98]
Breast cancer
(n = 160 patients)		Protein levelLevel of serum ADA was higher compared with healthy control (p < 0.05); level of ADA was significantly reduced upon tamoxifen treatment (p < 0.05) [99]
Breast cancer
(n = 58 patients)		Enzyme activityThe mean values for ADA activity (tissue and serum) of patients with breast cancer were significantly higher than those of the benign breast disease (p < 0.005) and healthy subjects (p < 0.0001) [100]
Breast cancer
(n= 19 triple-negative breast cancer) and MDA-MB-231 triple negative breast cancer cells		Enzyme activityPatients had higher plasma ADA2 activities and lower ADA1/ADA2 ratio at advanced stages of cancer development than in the initial stages; the activity of ADA changes during the interaction of tumor cells with lymphocytes, macrophages, and endothelial cells in vitro contributing to cancer progression. [102]
Colorectal cancer
(n = 40 patients)		Enzyme activityHigher in tumor than in healthy tissue (p < 0.01) [66]
Renal cell cancer
(n = 33 patients)		Serum enzyme activityADA activity was significantly higher in patients than in the healthy group (p < 0.001) [101]
Prostate cancer
(n = 68 patients)		Serum enzyme activityADA activity in serum of patients with prostate cancer and patients with bone metastases were significantly decreased (p < 0.05) when compared with the healthy control group [103]
Laryngeal cancer
(n = 15 patients)		Enzyme activityADA activity was decreased in cancerous tissues when compared with the cancer-free adjacent tissues (p < 0.025) [104]
Head and neck squamous cell carcinomas (n = 14)Protein levelWith progression of the disease, the expression of ADA/CD26 in effector T cells and CD3+ exosomes derived from T cells gets suppressed [105]
Lung cancer
(n = 13 patients with advanced stage)		Enzyme activityPatients with advanced stage of lung cancer exhibited a decrease in ADA activity in both lymphocyte and erythrocyte (p < 0.005) [106]
Lung cancer
(n = 43 patients)		Enzyme activityADA levels in bronchoalveolar lavage fluids were statistically higher compared with the non-malignant group (p < 0.001) and may be a diagnostic biomarker in lung malignancies [107]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Zhulai, G.; Oleinik, E.; Shibaev, M.; Ignatev, K. Adenosine-Metabolizing Enzymes, Adenosine Kinase and Adenosine Deaminase, in Cancer. Biomolecules 2022, 12, 418. https://0-doi-org.brum.beds.ac.uk/10.3390/biom12030418

AMA Style

Zhulai G, Oleinik E, Shibaev M, Ignatev K. Adenosine-Metabolizing Enzymes, Adenosine Kinase and Adenosine Deaminase, in Cancer. Biomolecules. 2022; 12(3):418. https://0-doi-org.brum.beds.ac.uk/10.3390/biom12030418

Chicago/Turabian Style

Zhulai, Galina, Eugenia Oleinik, Mikhail Shibaev, and Kirill Ignatev. 2022. "Adenosine-Metabolizing Enzymes, Adenosine Kinase and Adenosine Deaminase, in Cancer" Biomolecules 12, no. 3: 418. https://0-doi-org.brum.beds.ac.uk/10.3390/biom12030418

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop